• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

    11.91 +0.08 (+0.72%)
    Streaming Delayed Price Updated: 3:48 PM EDT, Mar 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 906,321
    Open 12.14
    Bid (Size) 11.91 (400)
    Ask (Size) 11.92 (500)
    Prev. Close 11.83
    Today's Range 11.89 - 12.26
    52wk Range 6.685 - 15.42
    Shares Outstanding 1,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment
    Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    3 Reasons to Avoid AMRX and 1 Stock to Buy Instead
    Amneal’s 34% return over the past six months has outpaced the S&P 500 by 30.9%, and its stock price has climbed to $13.16 per share. This performance may hav... 
    Via StockStory
    Topics Stocks

    Performance

    YTD
    -5.9%
    -5.9%
    1 Month
    -17.8%
    -17.8%
    3 Month
    -7.1%
    -7.1%
    6 Month
    +19.1%
    +19.1%
    1 Year
    +34.0%
    +34.0%

    More News

    Read More
    News headline image
    3 Value Stocks We’re Skeptical Of
    Via StockStory
    News headline image
    Amneal to Participate in Upcoming Investor Conference
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Reports Q4 2025 Earnings Beat on Strong Profitability ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Why Amneal (AMRX) Stock Is Trading Lower Today
    Via StockStory
    News headline image
    Amneal (AMRX) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Amneal (NASDAQ:AMRX) Beats Q4 CY2025 Sales Expectations
    Via StockStory
    News headline image
    Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    News headline image
    Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Supreme Court Strikes Down IEEPA Tariffs, Mandating Billions in Immediate Rebates
    Via MarketMinute
    Topics Bonds Economy Government
    News headline image
    3 Russell 2000 Stocks We Find Risky
    Via StockStory
    News headline image
    3 Small-Cap Stocks That Fall Short
    Via StockStory
    News headline image
    3 Cash-Producing Stocks That Concern Us
    Via StockStory
    News headline image
    3 Healthcare Stocks We Steer Clear Of
    Via StockStory
    Topics Stocks
    News headline image
    Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    News headline image
    Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    News headline image
    2 Reasons to Sell AMRX and 1 Stock to Buy Instead
    Via StockStory
    News headline image
    Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    News headline image
    1 Small-Cap Stock to Target This Week and 2 That Underwhelm
    Via StockStory
    News headline image
    Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    News headline image
    Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    News headline image
    3 Healthcare Stocks We’re Skeptical Of
    Via StockStory
    Topics Stocks
    News headline image
    Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire
    News headline image
    Amneal to Participate in Upcoming Investor Conferences
    From Amneal Pharmaceuticals LLC
    Via GlobeNewswire

    Frequently Asked Questions

    Is Amneal Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
    Yes, Amneal Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
    What exchange does Amneal Pharmaceuticals, Inc. - Class A Common Stock trade on?
    Amneal Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock?
    The ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock is AMRX on the Nasdaq Stock Market
    What is the current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock?
    The current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 11.91
    When was Amneal Pharmaceuticals, Inc. - Class A Common Stock last traded?
    The last trade of Amneal Pharmaceuticals, Inc. - Class A Common Stock was at 03/23/26 03:48 PM ET
    What is the market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock?
    The market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 11.91K
    How many shares of Amneal Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
    Amneal Pharmaceuticals, Inc. - Class A Common Stock has 12K shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.